Analyst Research Report Snapshot

Title:

GlaxoSmithKline Plc

Price:

$175.00

Provider:

MarketLine (a Datamonitor Company)

Date:

06 May 2015

Pages:

68

Type:

AcrobatPDF

Companies referenced:

GSK.L

Available for Immediate Download
Summary:

GlaxoSmithKline Plc - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360° view of the company. Features: - Detailed information on GlaxoSmithKline Plc required for business and competitor intelligence needs - A study of the major internal and external factors affecting GlaxoSmithKline Plc in the form of a SWOT analysis - An in-depth view of the business model of GlaxoSmithKline Plc including a breakdown and examination of key business segments - Intelligence on GlaxoSmithKline Plc’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors - News about GlaxoSmithKline Plc, such as business expansion, restructuring, and contract wins - Large number of easy-to-grasp charts and graphs that present important data and key trends Highlights: GlaxoSmithKline (GSK or 'the company') is a leading global provider of pharmaceutical and consumer health-related products. The company primarily operates in the US, Europe, Asia-Pacific. GSK is headquartered in Brentford, the UK, and employed 99,451 people as on December 31, 2013. The company recorded revenues of £26,505 million (approximately $41,427.3 million) during the financial year ended December 2013 (FY2013), an increase of 0.3% over FY2012. The operating profit of the company was £7,028 million (approximately $10,984.8 million) during FY2013, a decrease of 3.7% compared with FY2012. The net profit was £5,436 million (approximately $8,496.5 million) in FY2013, an increase of 20.8% over FY2012. In April 2014, GSK entered into an agreement with Novartis to acquire Novartis’s Vaccines business (excluding flu), to create a new consumer healthcare business by combining its consumer healthcare business with Novartis’s over the counter products and to divest its portfolio of oncology products to Novartis. Reasons to Purchase: - Gain understanding of GlaxoSmithKline Plc and the factors that influence its strategies - Track strategic initiatives of the company and latest corporate news and actions - Assess GlaxoSmithKline Plc as a prospective partner, vendor or supplier - Support sales activities by understanding your customers' businesses better - Stay up to date on GlaxoSmithKline Plc’s business structure, strategy and prospects

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.